MCID: CRB038
MIFTS: 37

Cerebral Ventricle Cancer

Categories: Cancer diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Cerebral Ventricle Cancer

MalaCards integrated aliases for Cerebral Ventricle Cancer:

Name: Cerebral Ventricle Cancer 12 54 15 17 74
Cerebral Ventricle Neoplasms 77 45 74
Intraventricular Tumor of Brain 12
Cerebral Ventricle Neoplasm 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3541
ICD9CM 36 191.5
MeSH 45 D002551
NCIt 51 C2937
SNOMED-CT 69 93748005
ICD10 34 C71.5

Summaries for Cerebral Ventricle Cancer

Disease Ontology : 12 A cerebrum cancer that is located in the cerebral ventricles.

MalaCards based summary : Cerebral Ventricle Cancer, also known as cerebral ventricle neoplasms, is related to choroid plexus cancer and respiratory system benign neoplasm. An important gene associated with Cerebral Ventricle Cancer is SYP (Synaptophysin), and among its related pathways/superpathways are Neuroscience and Neural Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Lenograstim and Sargramostim have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and bone, and related phenotype is Increased proliferation.

Wikipedia : 77 The ventricular system is a set of four interconnected cavities (ventricles) in the brain, where the... more...

Related Diseases for Cerebral Ventricle Cancer

Diseases related to Cerebral Ventricle Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 194)
# Related Disease Score Top Affiliating Genes
1 choroid plexus cancer 30.9 GFAP KCNJ13 RAD54L SMARCB1 TP53
2 respiratory system benign neoplasm 10.4 ENO2 SYP
3 bone benign neoplasm 10.4 ENO2 SYP
4 malignant pheochromocytoma 10.4 ENO2 SYP
5 connective tissue benign neoplasm 10.4 ENO2 SYP
6 cranial nerve malignant neoplasm 10.4 ENO2 SYP
7 mucinous ovarian cystadenoma 10.4 ENO2 SYP
8 olfactory neuroblastoma 10.4 ENO2 SYP
9 intraocular retinoblastoma 10.4 ENO2 SYP
10 gastric squamous cell carcinoma 10.4 ENO2 SYP
11 mixed ductal-endocrine carcinoma 10.4 ENO2 SYP
12 carcinoid syndrome 10.4 ENO2 SYP
13 horseshoe kidney 10.4 ENO2 SYP
14 extraskeletal ewing sarcoma 10.4 ENO2 SYP
15 pineoblastoma 10.4 GFAP SYP
16 pilomyxoid astrocytoma 10.4 GFAP SYP
17 binswanger's disease 10.4 GFAP SYP
18 traumatic brain injury 10.4 ENO2 GFAP
19 ileum cancer 10.4 ENO2 GFAP
20 granular cell tumor 10.4 ENO2 GFAP
21 dysgerminoma of ovary 10.4 ENO2 GFAP
22 chondroid chordoma 10.4 ENO2 SMARCB1
23 atypical choroid plexus papilloma 10.4 KCNJ13 SYP
24 carotid body cancer 10.4 ENO2 SYP
25 malignant sertoli cell tumor 10.4 ENO2 SYP
26 urinary bladder small cell neuroendocrine carcinoma 10.4 ENO2 SYP
27 auditory system cancer 10.4 ENO2 SYP
28 sinonasal undifferentiated carcinoma 10.4 ENO2 SYP
29 desmoplastic infantile ganglioglioma 10.4 GFAP SYP
30 extraventricular neurocytoma 10.4 GFAP SYP
31 vitreous disease 10.4 GFAP KCNJ13
32 pancreatic somatostatinoma 10.4 ENO2 SYP
33 cutaneous ganglioneuroma 10.4 ENO2 SYP
34 lung combined type small cell carcinoma 10.4 GFAP SYP
35 extrahepatic bile duct adenocarcinoma 10.4 ENO2 SYP
36 small cell carcinoma of the bladder 10.4 ENO2 SYP
37 papillary tumor of the pineal region 10.4 ENO2 SYP
38 sensory organ benign neoplasm 10.4 ENO2 SYP
39 intracranial cysts 10.4 ENO2 GFAP
40 orbital cancer 10.4 ENO2 SYP
41 middle ear adenoma 10.4 ENO2 SYP
42 primitive neuroectodermal tumor of the cervix uteri 10.4 ENO2 GFAP
43 myxosarcoma 10.4 SYP TP53
44 pulmonary blastoma 10.4 SYP TP53
45 large cell carcinoma with rhabdoid phenotype 10.3 ENO2 SMARCB1
46 liver angiosarcoma 10.3 ENO2 TP53
47 germ cell and embryonal cancer 10.3 ENO2 TP53
48 pulmonary large cell neuroendocrine carcinoma 10.3 ENO2 SYP
49 large cell neuroendocrine carcinoma 10.3 ENO2 SYP
50 gallbladder small cell carcinoma 10.3 ENO2 SYP

Graphical network of the top 20 diseases related to Cerebral Ventricle Cancer:



Diseases related to Cerebral Ventricle Cancer

Symptoms & Phenotypes for Cerebral Ventricle Cancer

GenomeRNAi Phenotypes related to Cerebral Ventricle Cancer according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased proliferation GR00094-A 8.8 NF2 SMARCB1 TP53

Drugs & Therapeutics for Cerebral Ventricle Cancer

Drugs for Cerebral Ventricle Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 79)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lenograstim Approved, Investigational Phase 3,Phase 1 135968-09-1
2
Sargramostim Approved, Investigational Phase 3 123774-72-1, 83869-56-1
3
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
4
Carboplatin Approved Phase 3 41575-94-4 10339178 38904 498142
5
Etoposide Approved Phase 3 33419-42-0 36462
6
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
7
Irinotecan Approved, Investigational Phase 3,Phase 2 100286-90-6, 97682-44-5 60838
8
Temozolomide Approved, Investigational Phase 3,Phase 1 85622-93-1 5394
9
Dactinomycin Approved, Investigational Phase 3 50-76-0 457193 2019
10
leucovorin Approved Phase 3 58-05-9 143 6006
11
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
12
Cisplatin Approved Phase 3 15663-27-1 2767 441203 84093
13
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
14
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
15
Doxil Approved June 1999 Phase 3 31703
16 Adjuvants, Immunologic Phase 3
17 Immunologic Factors Phase 3,Phase 2,Phase 1
18 Antineoplastic Agents, Alkylating Phase 3,Phase 1
19 Immunosuppressive Agents Phase 3
20 Antimitotic Agents Phase 3
21 Antirheumatic Agents Phase 3
22 Antineoplastic Agents, Phytogenic Phase 3
23 Etoposide phosphate Phase 3
24 Alkylating Agents Phase 3,Phase 1
25 Topoisomerase Inhibitors Phase 3,Phase 2
26 Antibiotics, Antitubercular Phase 3,Phase 1
27 Anti-Bacterial Agents Phase 3,Phase 1
28 topoisomerase I inhibitors Phase 3,Phase 2
29 Folate Phase 3
30 Antimetabolites, Antineoplastic Phase 3
31 Vitamin B9 Phase 3
32 Vitamin B Complex Phase 3
33 Nucleic Acid Synthesis Inhibitors Phase 3
34 Dermatologic Agents Phase 3
35 Folic Acid Antagonists Phase 3
36 Anti-Infective Agents Phase 3
37 Antimetabolites Phase 3
38
Bevacizumab Approved, Investigational Phase 2 216974-75-3
39
nivolumab Approved Phase 2 946414-94-4
40 Angiogenesis Modulating Agents Phase 2,Phase 1
41 Antineoplastic Agents, Immunological Phase 2
42 Angiogenesis Inhibitors Phase 2,Phase 1
43 Immunoglobulins Phase 2
44 Antibodies Phase 2
45 Antibodies, Monoclonal Phase 2
46
Vorinostat Approved, Investigational Phase 1 149647-78-9 5311
47
Bortezomib Approved, Investigational Phase 1 179324-69-7 387447 93860
48
Lenalidomide Approved Phase 1 191732-72-6 216326
49
Romidepsin Approved, Investigational Phase 1 128517-07-7 5352062
50
Mebendazole Approved, Vet_approved Phase 1 31431-39-7 4030

Interventional clinical trials:

(show all 25)
# Name Status NCT ID Phase Drugs
1 Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer Unknown status NCT01987596 Phase 3
2 Treatment of Tumors of the Choroid Plexus Epithelium Completed NCT00500890 Phase 3 Carboplatin;Cyclophosphamide;Etoposide;Vincristine
3 Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors Suspended NCT01014767 Phase 3 Carboplatin;Cisplatin;Cyclophosphamide;Dactinomycin;Doxorubicin;Etoposide;Irinotecan;Leucovorin;Methotrexate;Temozolomide;Vincristine
4 Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer Completed NCT00492089 Phase 2 bevacizumab;placebo
5 Irinotecan in Treating Children With Refractory Solid Tumors Completed NCT00004078 Phase 2 irinotecan hydrochloride
6 Immune Checkpoint Inhibitor Nivolumab in People With Select Rare CNS Cancers Recruiting NCT03173950 Phase 2 Nivolumab
7 p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors Completed NCT01975116 Phase 1 azurin-derived cell-penetrating peptide p28
8 RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma Completed NCT01119599 Phase 1 Gamma-Secretase Inhibitor RO4929097;Temozolomide
9 Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors Completed NCT01076530 Phase 1 vorinostat;temozolomide
10 Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma Completed NCT00994500 Phase 1 vorinostat;bortezomib
11 ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors Completed NCT00946335 Phase 1 veliparib;temozolomide
12 Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma Completed NCT00363272 Phase 1 ispinesib
13 Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors Completed NCT00100880 Phase 1 lenalidomide
14 Cilengitide in Treating Children With Refractory Primary Brain Tumors Completed NCT00063973 Phase 1 cilengitide
15 FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia Completed NCT00053963 Phase 1 romidepsin
16 Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors Completed NCT00052780 Phase 1 O6-benzylguanine;temozolomide
17 Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors Terminated NCT02255461 Phase 1 palbociclib isethionate
18 Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia Terminated NCT01088763 Phase 1 gamma-secretase/Notch signalling pathway inhibitor RO4929097;dexamethasone
19 Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain Tumors Terminated NCT00110032 Phase 1 EF5
20 Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors Completed NCT00919750
21 Collecting and Storing Tissue From Young Patients With Cancer Completed NCT00898755
22 Molecular-Guided Therapy for Childhood Cancer Active, not recruiting NCT02162732 Not Applicable
23 Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases Terminated NCT02967380 Not Applicable Gadobenate Dimeglumine;Gadobutrol
24 Yoga Therapy in Treating Patients With Malignant Brain Tumors Terminated NCT01234805 Not Applicable
25 Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors Withdrawn NCT02194452 Not Applicable

Search NIH Clinical Center for Cerebral Ventricle Cancer

Cochrane evidence based reviews: cerebral ventricle neoplasms

Genetic Tests for Cerebral Ventricle Cancer

Anatomical Context for Cerebral Ventricle Cancer

MalaCards organs/tissues related to Cerebral Ventricle Cancer:

42
Brain, Spinal Cord, Bone, Lung, Pineal, Kidney, Bone Marrow

The Foundational Model of Anatomy Ontology organs/tissues related to Cerebral Ventricle Cancer:

20
The Cerebral Ventricles

Publications for Cerebral Ventricle Cancer

Variations for Cerebral Ventricle Cancer

Expression for Cerebral Ventricle Cancer

Search GEO for disease gene expression data for Cerebral Ventricle Cancer.

Pathways for Cerebral Ventricle Cancer

Pathways related to Cerebral Ventricle Cancer according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.56 ENO2 GFAP NF2 RBFOX3 SYP
2 11.03 GFAP NES SYP

GO Terms for Cerebral Ventricle Cancer

Cellular components related to Cerebral Ventricle Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nuclear chromatin GO:0000790 8.8 RELA SMARCB1 TP53

Biological processes related to Cerebral Ventricle Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.16 RELA TP53
2 determination of adult lifespan GO:0008340 8.96 RAD54L TP53
3 DNA strand renaturation GO:0000733 8.62 RAD54L TP53

Molecular functions related to Cerebral Ventricle Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RNA polymerase II distal enhancer sequence-specific DNA binding GO:0000980 8.8 RELA SMARCB1 TP53

Sources for Cerebral Ventricle Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....